# E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma

> **NCT05388877** · PHASE1 · TERMINATED · sponsor: **Mayo Clinic** · enrollment: 13 (actual)

## Conditions studied

- Clinical Stage IV Cutaneous Melanoma AJCC v8
- Metastatic Malignant Neoplasm in the Brain
- Metastatic Malignant Neoplasm in the Central Nervous System
- Metastatic Melanoma

## Interventions

- **DRUG:** Dabrafenib
- **DRUG:** MEK-1/MEKK-1 Inhibitor E6201
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging

## Key facts

- **NCT ID:** NCT05388877
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-10-20
- **Primary completion:** 2024-11-19
- **Final completion:** 2025-06-02
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Financial issues
- **Last updated:** 2025-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05388877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05388877, "E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05388877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*